Predicting cancer organ tropism in mCRPC patients using triple-tracer PET imaging radiomics clustering from the 3TMPO cohort study.

B Brecht W. Chys (Cancer Research Center, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Québec City, QC, Canada) C Christopher Jean (Université de Sherbrooke, Sherbrooke, QC, Canada) F Fred Saad (Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal) Étienne Rousseau (Université de Sherbrooke, Sherbrooke, QC, Canada) P Patrick O. Richard A Atefeh Zamanian (CHU de Québec-Université Laval, Québec City, QC, Canada) F Frederic Pouliot (CHU de Québec-Université Laval Research Center, Quebec City, QC, Canada) B Brigitte Guérin (CIUSSS de l'Estrie - CHUS (Hôpital Fleurimont), Sherbrooke, QC, Canada) J Jean-Mathieu Beauregard (CHU de Quebec and Universite Laval, Quebec, QC, Canada) L Louis Archambault (Centre Hospitalier Universitaire (CHU) de Québec, Université Laval, Quebec, QC, Canada)

Abstract

29 Background: The 3TMPO study has characterized the prevalence of intrapatient intermetastatic heterogeneity (IIH) in mCRPC using a Triple-Tracer PET Imaging approach (PMID 39327017). Artificial intelligence based radiomics clustering can help to further characterize both IIH and interpatient cancer heterogeneity. In this study we have exploited the triple-tracer radiomics signatures to cluster patients and predict cancer organ tropism. Methods: 3TMPO is a multisite prospective observational study in which 41 mCRPC patients underwent 18 F-FDG, 68 Ga- PSMA–617 and 68 Ga-DOTATATE PET/CT scans. Calculations for hierarchic clustering used 9 vectors (SUVmax 18 F-FDG, SUVmean 18 F-FDG, SUVpeak 18 F-FDG, SUVmax 68 Ga- PSMA–617, SUVmean 68 Ga- PSMA–617, SUVpeak 68 Ga- PSMA–617, SUVmax 68 Ga-DOTATATE, SUVmean 68 Ga-DOTATATE, SUVpeak 68 Ga-DOTATATE on a total of 355 (35% nodal, 34% bone, 31% visceral) unique lesions. The model was trained on 284 (80.0%) lesions and used the remaining 71 (20%) for internal validation. Results: Based on triple tracer radiomics in each metastasis, 5 clusters could be identified with a total variance of 69.4%. Cluster 2 (C2) showed a triple-tracer signature strongly suggestive (specificity: 79%) of visceral metastasis, as did cluster 1 (C1) (specificity: 66%). Lesions in cluster 4 (C4) had a specificity of 74% for nodal metastasis. Nodal lesions in C2 showed, in contrast to C4, a vector activity more resemblant of liver lesions, putting forward the hypothesis that nodal disease with a C4 signature could be biologically different from lymph nodes with a C2 signature. Patients with lesions who expressed a C2 signature had a decrease in overall survival (OS) (3.1 months, n=4) compared to patients with lesions in other (C1, C3, C4 & C5) clusters (7.3 months, n = 37) (p-value = 0.06). Conclusions: An internally validated model using the 3TMPO 18 F-FDG, 68 Ga- PSMA–617 and 68 Ga-DOTATATE PET/CT imaging vectors to identify organ tropism clusters is presented. Different triple tracer signatures could be identified, some of which are associated with a shorter OS. Signatures of lymphatic lesions in M1c disease differ from M1a/b cases, suggesting that triple-tracer imaging can highlight differences in tumour biology. These findings favour our hypothesis that radiomic clusters could be used to predict organ tropisms and prognosis to guide precision medicine treatment intensification.

Article Details

Volume / Issue Vol. 44, Issue 7_suppl
Published March 01, 2026
Pages 29-29
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (10)

B

Brecht W. Chys

Cancer Research Center, Centre Hospitalier Universitaire (CHU) de Québec-Université Laval, Québec City, QC, Canada

C

Christopher Jean

Université de Sherbrooke, Sherbrooke, QC, Canada

F

Fred Saad

Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal

Étienne Rousseau

Université de Sherbrooke, Sherbrooke, QC, Canada

P

Patrick O. Richard

A

Atefeh Zamanian

CHU de Québec-Université Laval, Québec City, QC, Canada

F

Frederic Pouliot

CHU de Québec-Université Laval Research Center, Quebec City, QC, Canada

B

Brigitte Guérin

CIUSSS de l'Estrie - CHUS (Hôpital Fleurimont), Sherbrooke, QC, Canada

J

Jean-Mathieu Beauregard

CHU de Quebec and Universite Laval, Quebec, QC, Canada

L

Louis Archambault

Centre Hospitalier Universitaire (CHU) de Québec, Université Laval, Quebec, QC, Canada